Cargando…

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows

With the introduction of direct-acting antiviral agents (DAA), the rate of sustained virological response (SVR) in the treatment of hepatitis C virus (HCV) has radically improved to over 95%. Robust scientific evidence supports a beneficial role of SVR after interferon therapy in the progression of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guarino, Maria, Sessa, Anna, Cossiga, Valentina, Morando, Federica, Caporaso, Nicola, Morisco, Filomena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2018
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021774/ https://www.ncbi.nlm.nih.gov/pubmed/29962815 http://dx.doi.org/10.3748/wjg.v24.i24.2582

Ejemplares similares

Berberis aristata, Elaeis guineensis and Coffea canephora Extracts Modulate the Insulin Receptor Expression and Improve Hepatic Steatosis in NAFLD Patients: A Pilot Clinical Trial
por: Cossiga, Valentina, et al.
Publicado: (2019)

Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases
por: Imperatore, Nicola, et al.
Publicado: (2017)

Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case–control study
por: Morisco, Filomena, et al.
Publicado: (2018)

Liver resection is always a good choice for hepatocellular carcinoma (HCC) patients regardless of Barcelona Clinic Liver Cancer (BCLC) stage: the therapeutic hierarchy
por: Guarino, Maria, et al.
Publicado: (2020)

Endoscopic retrograde cholangiopancreatography, lights and shadows: Handle with care
por: Salerno, Raffaele, et al.
Publicado: (2019)

Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions
por: Cossiga, Valentina, et al.
Publicado: (2023)

Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?
por: Butt, Amna Subhan, et al.
Publicado: (2018)

Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents
por: Cossiga, Valentina, et al.
Publicado: (2022)

Use of Telemedicine for Chronic Liver Disease at a Single Care Center During the COVID-19 Pandemic: Prospective Observational Study
por: Guarino, Maria, et al.
Publicado: (2020)

Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!
por: Guarino, Maria, et al.
Publicado: (2022)

Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
por: Muzica, Cristina Maria, et al.
Publicado: (2020)

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
por: Kamal, Ahmed, et al.
Publicado: (2022)

COVID-19 and Fatty Liver Disorders
por: Guarino, Maria, et al.
Publicado: (2023)

If so many are “few,” how few are “many”?
por: Heim, Stefan, et al.
Publicado: (2015)

Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
por: Baumert, Thomas F., et al.
Publicado: (2017)

Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates
por: Gadiparthi, Chiranjeevi, et al.
Publicado: (2018)

The many hues of plant heterochromatin
por: Bennetzen, Jeffrey L
Publicado: (2000)

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Omics era in type 2 diabetes: From childhood to adulthood
por: Passaro, Antonio Paride, et al.
Publicado: (2021)

How many genes in a genome?
por: Oliver, Brian, et al.
Publicado: (2004)

Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals
por: Cerrito, Lucia, et al.
Publicado: (2021)

Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review
por: Spera, Anna Maria
Publicado: (2022)

Macrotrabecular-Massive Hepatocellular Carcinoma: Light and Shadow in Current Knowledge
por: Sessa, Anna, et al.
Publicado: (2022)

Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice
por: Invernizzi, Federica, et al.
Publicado: (2022)

Night shift work and sickness absence – many for the few or few for the many?
por: Larsen, A D, et al.
Publicado: (2023)

SnoPatrol: how many snoRNA genes are there?
por: Gardner, Paul P, et al.
Publicado: (2010)

The one, the few and the many
por: Poole, Norman
Publicado: (2020)

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis
por: Morisco, Filomena, et al.
Publicado: (2014)

Telemedicine in the COVID-19 era: Taking care of children with obesity and diabetes mellitus
por: Umano, Giuseppina Rosaria, et al.
Publicado: (2021)

c-Rel and its many roles in cancer: an old story with new twists
por: Hunter, Jill E, et al.
Publicado: (2016)

The many and the few : political participation in republican Buenos Aires /
por: Sábato, Hilda
Publicado: (2001)

COVID-19 and pediatric fatty liver disease: Is there interplay?
por: Di Sessa, Anna, et al.
Publicado: (2021)

Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study
por: Cossiga, Valentina, et al.
Publicado: (2022)

Drugs Many: Remedies Few
Publicado: (1895)

For the Many, Not the Few: Patient Empowerment
por: Horgan, Denis, et al.
Publicado: (2017)

The future of entrepreneurship: the few or the many?
por: Kuratko, Donald F., et al.
Publicado: (2021)

The Combination of Berberine, Tocotrienols and Coffee Extracts Improves Metabolic Profile and Liver Steatosis by the Modulation of Gut Microbiota and Hepatic miR-122 and miR-34a Expression in Mice
por: Cossiga, Valentina, et al.
Publicado: (2021)

Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease
por: Cossiga, Valentina, et al.
Publicado: (2023)

Advances in the Development of Antiviral Compounds for Rotavirus Infections
por: Tohmé, María Julieta, et al.
Publicado: (2021)

Metabolic-associated fatty liver disease from childhood to adulthood: State of art and future directions
por: Lanzaro, Francesca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fk9gkqbf91oe4s9msmp15ehsau